Document:

Offer Letter

 Exhibit 10.102 
 August 11, 2006 
 Mr. Juan J. Soto 
 Dear Juan: 
 On behalf of RITA Medical Systems, Inc. (the “Company”), I am pleased to offer you the position of
Executive Vice President of Worldwide Sales. We look forward to your future success in this position. 
 The terms of your new position with
the Company are as set forth below: 
 1. Position. 
 a. You will become the Executive Vice President of Worldwide Sales, working out of the Company’s office in Fremont, California. You will
report to the Company’s Chief Executive Officer. 
 b. You agree to the best of your ability and experience that you will at all times
loyally and conscientiously perform all of the duties and obligations required of and from you pursuant to the express and implicit terms hereof, and to the reasonable satisfaction of the Company. During the term of your employment, you further
agree that you will devote all of your business time and attention to the business of the Company, the Company will be entitled to all of the benefits and profits arising from or incident to all such work services and advice, you will not render
commercial or professional services of any nature to any person or organization, whether or not for compensation, without the prior written consent of the Company’s Board of Directors, and you will not directly or indirectly engage or
participate in any business that is competitive in any manner with the business of the Company. Nothing in this letter agreement will prevent you from accepting speaking or presentation engagements in exchange for honoraria or from serving on boards
of charitable organizations, or from owning no more than one percent (1%) of the outstanding equity securities of a corporation whose stock is listed on a national stock exchange. 
 2. Start Date. Subject to fulfillment of any conditions imposed by this letter agreement, you will commence this new position with the
Company on September 1, 2006. 
 3. Proof of Right to Work. For purposes of federal immigration law, you will be required
to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business days of your date of hire, or our employment relationship
with you may be terminated. 
 4. Compensation. 
 a. Base Salary. You will be paid a monthly gross salary of $16,666.67 which is equivalent to $200,000 on an annualized basis. Your salary will be payable in two equal payments on the 15th and the last day of the month. 
 b. Commission. You will receive a commission according to the Company’s Sales Commission Plan, which is in effect at the time the commission is earned. This plan may be revised by the Company from
time to time, at its sole discretion. 

 c. One-Time Relocation Bonus. You will receive a one-time relocation cash bonus of $50,000
(less appropriate withholdings) payable within ten days of the date on which you sign this letter agreement. 
 d. Annual
Review. Your base salary will be reviewed as part of the Company’s normal annual salary review process. 
 5. Stock
Options. 
 a. Option Grants. Subject to the discretion of the Company’s Board of Directors, you may be eligible
to receive grants of stock options or purchase rights from time to time in the future, on such terms and subject to such conditions as the Board of Directors shall determine as of the date of any such grant. 
 6. Benefits. 
 a.
Insurance Benefits. The Company will make available to you medical, dental, vision, life and long-term disability insurance benefits. More detailed information will be provided in a new-hire packet that will be given to you after your
acceptance of this offer. 
 b. Vacation. You will be entitled to 3 weeks paid vacation per year, pro-rated for the remainder
of this calendar year. Vacation accrues as follows: five (5) hours accrue per pay period from your date of hire. 
 c. 401K
Retirement Plan. You will be eligible to participate in the Company’s employee-contribution 401K Retirement Plan beginning on the first January 1, April 1, July 1, or October 1 following commencement of
your employment. 
 d. Employee Stock Purchase Plan. You will be eligible to participate in the Company’s Employee Stock
Purchase Plan beginning on the first February 1 or August 1 following commencement of your employment. 
 7. Severance
Benefits. In the event that the Company or its successor in interest terminates your employment without Cause (as defined below), then you will be entitled to receive continuation of your then-current monthly base salary for six
(6) months following your termination date. This salary continuation shall be contingent upon confirmation to the Company’s satisfaction that you are actively seeking Full-Time Employment, which for purposes of this Offer Letter shall be
defined as at least thirty-five (35) hours per week of compensated labor, including consulting and other work. In the event that you commence Full-Time Employment, your salary continuation will cease. In addition, following the termination of
your employment, the Company will pay your COBRA insurance premiums (provided that you elect such coverage) until the earlier of (A) six (6) months following your termination date or (B) the date on which you become eligible for
insurance benefits from another employer. Upon termination of your employment with the Company, you will be entitled to receive benefits only as set forth herein or as otherwise provided by applicable law. Your entitlement to these severance
benefits will be conditioned upon your execution and delivery to the Company of a general mutual release of all claims (provided that the Company shall not be required to release any claims arising from a material breach by you of the
Confidentiality Agreement (as defined below)). 
 For purposes of this Offer Letter, “Cause” shall mean (i) gross
negligence or willful misconduct in the performance of your duties to the Company where such gross negligence or willful misconduct has resulted or is likely to result in substantial and material damage to the Company or its subsidiaries,
(ii) repeated unexplained or unjustified absence from the Company, (iii) a material and willful violation of any federal or state law; (iv) commission of any act of fraud with respect to the Company; or (v) conviction of a felony
or a crime involving moral turpitude causing material harm to the standing and reputation of the Company, in each case as determined in good faith by the Board of Directors of the Company. 

 8. Reimbursement for Return to United Kingdom. The Company will reimburse you for you and
your family’s actual expenses incurred in relocating from the Bay Area, California, back to the United Kingdom (the “Return Expenses”) if: 
 a. RITA Medical Systems, Inc. enters a Change of Control (as defined below) agreement with any other company; 
 b. As of the date of the Change of Control agreement, you remain employed by RITA Medical Systems, Inc.; 
 c. Within 180 days after
the date of the Change of Control agreement, you are involuntarily terminated without Cause by Rita Medical Systems, Inc. or its acquirer; and 
 d. Within 90 days after the date of your termination, you move your residence from the United States to the United Kingdom. 
 Such
reimbursement shall not exceed $50,000. Return Expenses shall include any moving expenses incurred as a result of the return of you and your spouse and children to the United Kingdom, within 90 days of your termination without Cause from RITA
Medical Systems, Inc. or its acquirer. Such Return Expenses may also include payment by RITA Medical Systems, Inc. or its acquirer, of the remainder of the first year of your initial one-year housing lease in the Bay Area, California, should such
termination without Cause occur during your first year of employment with RITA Medical Systems, Inc. RITA Medical Systems, Inc. or its acquirer shall make such lease payment to the extent such payment does not cause your Return Expenses to exceed
$50,000. 
 Your entitlement to Return Expenses will also be conditioned upon your execution and delivery to RITA Medical Systems, Inc. or
its acquirer of a general mutual release of all claims (provided that RITA Medical Systems, Inc. or its acquirer shall not be required to release any claims arising from a material breach by you of the Confidentiality Agreement (as defined below)),
and your submission of original receipts to RITA Medical Systems, Inc. or its acquirer within 60 days of the date the expense is incurred. 
 9. Change of Control. “Change of Control” shall mean the consummation of any of the following events: 
 a.
Ownership. Any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) is or becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act), directly or
indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities without the approval of the Board of Directors of the
Company; or 
 b. Merger/Sale of Assets. A merger or consolidation of the Company whether or not approved by the Board of Directors of
the Company, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities
of the surviving entity) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the
Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets. 
 10. Confidential Information and Invention Assignment Agreement. Your acceptance of this offer and commencement of employment with the
Company is contingent upon the execution, and delivery to an officer of the Company, of the Company’s Confidential Information and Invention Assignment Agreement, a copy of which is enclosed for your review and execution (the
“Confidentiality Agreement”), prior to or on your Start Date. 

 11. Confidentiality. You agree to follow the Company’s strict policy that employees
must not disclose, either directly or indirectly, any information regarding compensation of, or stock purchase or option allocations to other employees of the Company, should you, by virtue of performance of your duties, learn about such
compensation or stock option information of other employees of the Company. 
 12. At-Will Employment. Your employment with the
Company will be on an “at will” basis, meaning that either you or the Company may terminate your employment at any time for any reason or no reason, with or without notice, with or without cause, without further obligation or liability.

 We are all delighted to be able to extend you this offer and look forward to working with you. To indicate your acceptance of the
Company’s offer, please sign and date this letter in the space provided below, and return it to me, along with a signed and dated copy of the Confidentiality Agreement. This letter, together with the Confidentiality Agreement, set forth the
terms of your employment with the Company and supersedes any prior representations or agreements, whether written or oral. This letter may not be modified or amended except by a written agreement, signed by the Company and by you. 
  

			
	Very truly yours,
	
	RITA MEDICAL SYSTEMS, INC.
		
	By:	 	 /S/    JOSEPH DEVIVO

		 	Joseph DeVivo
	Title:	 	Chief Executive Officer

  

	
	ACCEPTED AND AGREED:
	JUAN J. SOTO
	
	 /S/    JUAN J.
SOTO

	 Signature

	
	 August 11, 2006

	 Date

 Enclosure: Confidential Information and Invention Assignment AgreementSupplemental Indenture, dated as of October 31, 2006

 Exhibit 4.10 
 Execution Copy 
 INTCOMEX, INC. 
 INTCOMEX HOLDINGS, LLC 
 INTCOMEX HOLDINGS SPC-I, LLC 
 SOFTWARE BROKERS OF AMERICA, INC. 
  

 11 3/4% SECOND PRIORITY SENIOR SECURED NOTES DUE 2011 
  

 SUPPLEMENTAL INDENTURE 

DATED AS OF OCTOBER 31, 2006 
  

 THE BANK OF NEW YORK 
 Trustee 

 This Supplemental Indenture, dated as of October 31, 2006, is by and among Intcomex, Inc., a
Delaware corporation (including any successor thereto, the “Company”), Intcomex Holdings, LLC, a Delaware limited liability company (including any successor thereto, “Holdings”), Intcomex Holdings SPC-I, LLC, a
Delaware limited liability company (including any successor thereto, “SPC”), and Software Brokers of America, Inc., a Delaware corporation (including any successor thereto, “SBA” and, together with Holdings and SPC,
the “Guarantors”), and The Bank of New York, a New York banking corporation as trustee (the “Trustee”), to the Indenture, dated as of August 25, 2005, among the Company, the Guarantors and the Trustee (the
“Base Indenture”). 
 W I T N E S S E T H: 
 WHEREAS, Section 9.1(2) of the Base Indenture provides that the Company, the Guarantors and the Trustee may enter into a supplemental indenture to the Base Indenture, without the consent of any Holders, in order
to add to the covenants of the Company for the benefit of the Holders; 
 WHEREAS, Section 9.1(9) of the Base Indenture provides that
the Company, the Guarantors and the Trustee may enter into a supplemental indenture to the Base Indenture, without the consent of any Holders, in order to cure any ambiguity, to correct or supplement any provision in the Base Indenture which may be
defective or inconsistent with any other provision in the Base Indenture, or to make any other provisions with respect to matters or questions arising under the Base Indenture, provided that such action shall not adversely affect the
interests of the Holders in any material respect, as determined in good faith by the Board of Directors of the Company; 
 WHEREAS, in
connection with an application to the Securities and Exchange Commission (the “Commission”) for an exemption from provisions of the Trust Indenture Act of 1939, as amended (the “TIA”), in connection with certain
releases of the Lien arising under the Security Documents, the Company and the Guarantors wish to amend the Base Indenture pursuant to Sections 9.1(2) and 9.1(9) of the Base Indenture; 
 WHEREAS, the Company and the Guarantors, in addition, wish to correct the definition of “Credit Agreement” in the Base Indenture; 

WHEREAS, the Company and the Guarantors have determined that the amendments contemplated herein will not adversely affect the interests of the Holders
in any material respect and accordingly may be entered into without the consent of any Holders; 
 WHEREAS, the Company and each of the
Guarantors have duly authorized the execution and delivery of this Supplemental Indenture; and 
 WHEREAS, all things necessary to make this
Supplemental Indenture a valid agreement of the Company and the Guarantors, in accordance with its terms, have been done. 
 NOW,
THEREFORE, the Company, the Guarantors and the Trustee agree as follows for the benefit of each other and for the equal and ratable benefit of the holders of (i) the Company’s 11 3/4% Second Priority Senior Secured Notes due 2011
issued on August 25, 2005 (the “Initial 

  

 1 

 
Notes”) and (ii) Exchange Notes, Private Exchange Notes and Additional Notes (together with the Initial Notes, the
“Notes”): 
 ARTICLE I 
 AMENDMENTS 
 SECTION 1.1 Definitions. 
 (a) Credit Agreement. The definition of “Credit Agreement” in Section 1.1 of the Base Indenture is hereby deleted in its entirety and replaced with the following: 
 ““Credit Agreement” means the Credit Agreement, dated as of August 25, 2005, between SBA and Comerica Bank,
together with all related notes, letters of credit, security documents, guarantees, and any other related agreements and instruments executed and delivered in connection therewith, in each case as amended, modified, supplemented, refinanced,
refunded or replaced in whole or in part from time to time.” 
 (b) New Definitions. Section 1.1 of the Base
Indenture is hereby amended by adding to Section 1.1 the following definitions: 
 ““Eligible Domestic
Restricted Subsidiary” means (1) SBA and (2) any future Domestic Restricted Subsidiary that (a) executes supplemental Security Documents on terms substantially similar to those executed by the other Domestic Restricted
Subsidiaries in accordance with Section 4.16 of this Indenture and (b) has obtained an order from the Director of the Division of Corporation Finance of the Commission exempting it from the provisions of Section 314(d) of the TIA, or
any successor provision, with respect to certain dispositions of Collateral made in accordance with Section 10.4 of this Indenture.” 
 ““Guarantor Officers’ Certificate” means, with respect to any Eligible Domestic Restricted Subsidiary, a certificate to be delivered upon the occurrence of certain events as set forth in
this Indenture, signed on behalf of such Eligible Domestic Restricted Subsidiary by two Officers of such Eligible Domestic Restricted Subsidiary, one of whom must be the principal executive officer, the principal financial officer or the principal
accounting officer of such Eligible Domestic Restricted Subsidiary.” 
 SECTION 1.2 Provision of Financial Information. The first
paragraph of Section 4.3 of the Base Indenture is hereby deleted in its entirety and replaced with the following: 
 “Whether or not required by the rules and regulations of the Commission, so long as any Notes are outstanding (unless defeased in a Legal Defeasance), the Company will have its annual consolidated financial statements audited, and its
interim financial statements reviewed, by a nationally recognized firm of independent accountants and will furnish to the Trustee and the Holders, within 90 calendar days after the end of each fiscal year of the Company and within 45 calendar days
after the end of each of the first three fiscal quarters of each fiscal year of the Company, (a) all quarterly and annual consolidated financial statements prepared in accordance with GAAP that would be 

  

 2 

 
required to be contained in a filing with the Commission on Forms 10-Q and 10-K if the Company were required to file those Forms, including a
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” and, with respect to the annual consolidated financial statements only, an audit report on the annual financial statements by the Company’s
certified independent accountants and (b) from and after the Registration Statement Effective Date all other information that would be required to be contained in a filing with the Commission on Form 8-K if the Company were required to file
that Form.” 
 SECTION 1.3 Disposition of Collateral. Section 10.4 of the Base Indenture is hereby deleted in its entirety
and replaced with the following: 
 “SECTION 10.4 Certificates of the Company. 
 (a) The Company and the Guarantors shall comply (or cause compliance) with Section 313(b) of the TIA, relating to reports, and
Section 314(d) of the TIA, relating to the release of property or securities from the lien and security interest of the Security Documents and relating to the substitution therefor of any property or securities to be subjected to the lien and
security interest of the Security Documents. 
 (b) Notwithstanding the above provisions, so long as no Event of Default shall
have occurred and be continuing or would result therefrom and so long as such transaction would not violate this Indenture, each Eligible Domestic Restricted Subsidiary may, to the extent permitted by applicable law, without any action or consent by
the Trustee: 
 (i) sell or dispose of in the ordinary course of business, free from the Liens of the Security Documents, any
machinery, equipment, furniture, apparatus, tools or implements, materials or supplies or other similar property (“Subject Property”), that, in the Eligible Domestic Restricted Subsidiary’s reasonable opinion, may have become
obsolete, worn-out, surplus or no longer used in the conduct of its business upon replacing the same with, or substituting for the same, new Subject Property subject to the Lien of the Security Documents as After-Acquired Property not necessarily of
the same character but being of at least equal value and utility as the Subject Property so disposed of, which new Subject Property shall without further action become Collateral subject to the Lien and security interest of the Security Documents;

 (ii) abandon, sell, assign, transfer, license or otherwise dispose of in the ordinary course of business, free from the
Liens of the Security Documents, any personal property that is not used or useful in the conduct of its business, that is not necessary for the maintenance of its earnings and that is not material to the conduct of the business of the Eligible
Domestic Restricted Subsidiaries, taken as a whole, upon replacing the same with, or substituting for the same, new personal property subject to the Lien of the Security Documents as After-Acquired Property not necessarily of the same character but
being of at least equal value and utility as the personal property so disposed of, which new personal property 

  

 3 

 
shall without further action become Collateral subject to the Lien and security interest of the Security Documents; 
 (iii) sell, transfer or otherwise dispose of inventory in the ordinary course of business; 
 (iv) sell, collect, liquidate, factor or otherwise dispose of “Accounts” (as defined in the Security Documents) and accounts
receivable in the ordinary course of business; and 
 (v) utilize (including for the scheduled payment of Debt) cash proceeds
from the activities listed in clauses (iii) and (iv) above constituting Collateral in the ordinary course of business in a manner not otherwise prohibited by any Security Document or the Indenture. 
 In the case of transactions permitted by this Section 10.4(b), each Eligible Domestic Restricted Subsidiary shall deliver to the Trustee,
within 15 days after the end of each of the six-month periods ended on June 30 and December 31 in each year, a Guarantor Officers’ Certificate to the effect that all transactions effected by such Eligible Domestic Restricted
Subsidiary pursuant to this Section 10.4(b) during the preceding six-month period were made in the ordinary course of business and were not prohibited by this Indenture and that all proceeds therefrom were used by such Eligible Domestic
Restricted Subsidiary in its business, to make payments on the Notes or as otherwise permitted herein or by the Security Documents. The Company shall provide the Trustee with a copy of any exemption from the requirements of Section 314(d) of
the TIA granted by the Commission and promptly inform the Trustee of any rescission or termination of, or amendment to, such exemption. 
 (c) The fair value of Collateral released from the Liens of the Security Documents as to which opinions or certificates are not delivered prior to the applicable date of determination in reliance upon
Section 10.4(b) shall not be considered in determining whether the aggregate fair value of Collateral released from the Liens of the Security Documents in any calendar year exceeds the 10% threshold specified in Section 314(d)(l) of
the TIA; provided that the right of any Eligible Domestic Restricted Subsidiary to rely on this sentence at any time is conditioned upon such Eligible Domestic Restricted Subsidiary’s having furnished to the Trustee the Guarantor
Officers’ Certificates described in Section 10.4(b) that were required to be furnished to the Trustee at or prior to such time.” 
 (d) In the event that the Lien on the Capital Interests of any Subsidiary pledged as Collateral pursuant to the Security Documents to secure the Notes is reduced in scope pursuant to Section 10.3(f) of this
Indenture, the Company or the Guarantor that is the pledgor with respect to such Lien shall, for so long as required by applicable law, deliver a certificate or an opinion to the Trustee in compliance with Section 314(d) of the TIA in
connection therewith. 
  

 4 

 ARTICLE II 
 MISCELLANEOUS 
 SECTION 2.1 Incorporation of Definitions. For all purposes of this Supplemental
Indenture, capitalized terms used but not defined in this Supplemental Indenture shall have the meanings specified in the Base Indenture. If any term is defined in this Supplemental Indenture and in the Base Indenture, such term shall have the
meaning assigned to it in this Supplemental Indenture. 
 SECTION 2.2 Supplemental Indenture. This Supplemental Indenture constitutes
an integral part of the Base Indenture and shall be construed in connection with and as part of the Base Indenture. If any provision of this Supplemental Indenture conflicts with any provision of the Base Indenture, the provisions of this
Supplemental Indenture shall control. 
 SECTION 2.3 Governing Law. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED IN SUCH STATE WITHOUT REGARD TO CONFLICTS OF LAW PRINCIPLES THEREOF THAT WOULD REQUIRE APPLICATION OF THE LAWS OF ANOTHER STATE. 

SECTION 2.4 Ratification. Except as expressly amended hereby, each provision of the Base Indenture and each Note shall remain in full force and
effect, as amended hereby, and the Base Indenture, as supplemented, and the Notes are in all respects agreed to, ratified and confirmed by the parties hereto. 
 SECTION 2.5 Counterpart Originals. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement.

 SECTION 2.6 Concerning the Trustee. The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity
or sufficiency of this Supplemental Indenture or for or in respect of the Recitals hereto, all of which are made solely by the Company and the Guarantors. 
 [Signature Page Follows] 
  

 5 

 SIGNATURES 
 Dated as of October 31, 2006 
  

			
	INTCOMEX, INC.
		
	By:	 	/s/ Michael Shalom
		 	 Name: Michael Shalom
 Title:   President

  

			
	 INTCOMEX HOLDINGS, LLC

		
	By:	 	/s/ Michael Shalom
		 	 Name: Michael Shalom
 Title:   President

  

			
	 INTCOMEX HOLDINGS SPC-I, LLC

		
	By:	 	/s/ Michael Shalom
		 	 Name: Michael Shalom
 Title:   President

  

			
	 SOFTWARE BROKERS OF AMERICA, INC.

		
	By:	 	/s/ Michael Shalom
		 	 Name: Michael Shalom
 Title:   Vice President

  

			
	 THE BANK OF NEW YORK, as Trustee

		
	By:	 	/s/ Giovanni Barris
		 	 Name: Giovanni Barris
 Title: Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]